| Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. | |
| | |
MedLine Citation:
|
PMID: 20009905 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer. PATIENTS AND METHODS: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m2; gemcitabine, 500 mg/m2 (day 1); and oxaliplatin, 70 mg/m2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease. RESULTS: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carboplatin-sensitive disease, an overall response (OR) of 83.3%, a progression-free survival of 10.6 months, and an overall survival of 18.9 months were observed. In patients with carboplatinum-resistant disease, an OR was seen in 38.9% with a progression-free survival of 5.3 months and an overall survival of 16.3 months. Patients with platinum-refractory disease (progression under previous carboplatinum therapy, n = 13) had an OR of 23%, whereas patients with objective response but relapse less than 6 months after carboplatinum therapy had an OR of 80.0%. Grade 3 and 4 toxicities were only observed for anemia (6.7%), neutropenia (20.0%), thrombopenia, peripheral neuropathy, and diarrhea (16.7%). No neutropenic fever or treatment-related death occurred. CONCLUSIONS: In comparison with current standard protocols, a combination of docetaxel, gemcitabine, and oxaliplatin showed considerably higher efficacy without remarkable increased toxicity; particularly for patients with early relapse after a platinum-containing therapy. |
| | |
Authors:
|
Gregor Seliger; Lutz P Mueller; Thomas Kegel; Eva J Kantelhardt; Axel Grothey; Regina Groe; Hans-Georg Strauss; Heinz Koelbl; Christoph Thomssen; Hans-Joachim Schmoll |
Related Documents
:
|
12394255 - Epirubicin/docetaxel regimen in progressive breast cancer-a phase ii study. 17551305 - Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of th... 10811675 - Prospective randomized trial of docetaxel versus best supportive care in patients with ... 15655935 - Pemetrexed in second-line treatment of non-small-cell lung cancer. 12161935 - The role of combined method in organ-sparing treatment of muscle-invasive bladder cance... 3433365 - Primary lymphomas of the brain: a clinico-pathologic review of 37 cases. |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Multicenter Study |
Journal Detail:
|
Title: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Volume: 19 ISSN: 1525-1438 ISO Abbreviation: Int. J. Gynecol. Cancer Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2009-12-16 Completed Date: 2010-03-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111626 Medline TA: Int J Gynecol Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 1446-53 Citation Subset: IM |
Affiliation:
|
Department of Gynecology, Martin Luther University Halle-Wittenberg, Halle, Germany. gregor.seliger@medizin.uni-halle.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Deoxycytidine / administration & dosage, analogs & derivatives Fallopian Tube Neoplasms / drug therapy*, pathology Female Humans Middle Aged Neoplasm Invasiveness Neoplasm Staging Organoplatinum Compounds / administration & dosage Ovarian Neoplasms / drug therapy*, pathology Paclitaxel / administration & dosage Peritoneal Neoplasms / drug therapy*, pathology Prognosis Prospective Studies Risk Factors Taxoids / administration & dosage Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Organoplatinum Compounds; 0/Taxoids; 103882-84-4/gemcitabine; 114977-28-5/docetaxel; 33069-62-4/Paclitaxel; 63121-00-6/oxaliplatin; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Can we diagnose invasive cervical cancer during pregnancy as precise as in nonpregnant women?: mater...
Next Document: Mastectomy approach with Y-shaped incision: a technique designed for women with obesity.